Nabi Biopharmaceuticals (NABI) On Track to Offer Market’s First Nicotine Vaccine for Smoking Cessation
Nabi Biopharmaceuticals, specializing in using the immune system to develop products that counteract nicotine addiction and gram-positive bacterial infections, announced today that it has completed enrollment in the second Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine). NicVAX is Nabi’s proprietary candidate vaccine for treating nicotine addiction. Enrollment for the first clinical trial was completed in July. NicVAX works by getting the immune system to produce antibodies that block nicotine from reaching receptors in the brain, receptors that release dopamine and other stimulants. When fewer such stimulants are released, the pleasurable and addictive effects of nicotine are diminished, making…